Share:
Share this content in WeChat
X
Clinical Article
Value of different ADC to access complete response of rectal cancer after neoadjuvant therapy: A Meta analysis
LI Jipin  ZHANG Wenkai  ZHUANG Leyi  SUN Yihua  HE Dong  WANG Xiang 

Cite this article as: Li JP, Zhang WK, Zhuang LY, et al. Value of different ADC to access complete response of rectal cancer after neoadjuvant therapy: A Meta analysis[J]. Chin J Magn Reson Imaging, 2022, 13(8): 36-42, 54. DOI:10.12015/issn.1674-8034.2022.08.007.


[Abstract] Objective To summarize the available evidence and verify the reliability of apparent diffusion coefficient (ADC) at evaluating complete response in patients with locally advanced rectal cancer treated with neoadjuvant therapy by using Meta-analysis.Materials and Methods A systematic search in PubMed, Embase, The Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Biomedical Literature Database (CBM) and www.cqvip.com was performed to retrieve related studies. The literature was screened according to the inclusion and exclusion criteria, and the data was extracted as well. The methodological quality of the included articles was assessed by using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Study heterogeneity was evaluated, when threshold effects were excluded, the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) of the hierarchical summary receiver-operating characteristic curve (HSROC), as well as their corresponding 95% confidence intervals (95% CI) were calculated.Results Thirty-four diagnostic studies involving 1914 patients were included. The ADC indicators included before and after neoadjuvant therapy (pretreatment ADC and posttreatment ADC, pre-ADC and post-ADC), as well as the change ratio between the pre-and post-ADC (ΔADC). The pooled SEN and SPE were 0.76 and 0.68 for pre-ADC; 0.82 and 0.77 for post-ADC; 0.83 and 0.75 for ΔADC.Conclusions Among the different ADC indicators, the diagnostic value of post-ADC and ΔADC was higher than pre-ADC, however, pre-ADC could be used as a predictive tool for tumor response before treatment.
[Keywords] rectal cancer;apparent diffusion coefficient;complete response;diagnostic test;Meta-analysis

LI Jipin1   ZHANG Wenkai1   ZHUANG Leyi1   SUN Yihua1   HE Dong1   WANG Xiang2*  

1 The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China

2 Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou 730030, China

Wang X, E-mail: wangxiang@lzu.edu.cn

Conflicts of interest   None.

Received  2022-02-23
Accepted  2022-07-26
DOI: 10.12015/issn.1674-8034.2022.08.007
Cite this article as: Li JP, Zhang WK, Zhuang LY, et al. Value of different ADC to access complete response of rectal cancer after neoadjuvant therapy: A Meta analysis[J]. Chin J Magn Reson Imaging, 2022, 13(8): 36-42, 54.DOI:10.12015/issn.1674-8034.2022.08.007

[1]
Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer[J/OL]. JAMA Oncol, 2018, 4 [2022-02-20]. https://jamanetwork.com/journals/jamaoncology/fullarticle/2675916. DOI: 10.1001/jamaoncol.2018.0071.
[2]
Keller DS, Berho M, Perez RO, et al. The multidisciplinary management of rectal cancer[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(7): 414-429. DOI: 10.1038/s41575-020-0275-y.
[3]
Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22: 702-715. DOI: 10.1016/S1470-2045(21)00079-6.
[4]
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16(7): 874-901. DOI: 10.6004/jnccn.2018.0061.
[5]
Goldenberg BA, Holliday EB, Helewa RM, et al. Rectal Cancer in 2018: A Primer for the Gastroenterologist[J]. Am J Gastroenterol, 2018, 113(12): 1763-1771. DOI: 10.1038/s41395-018-0180-y.
[6]
Lee JB, Kim HS, Ham A, et al. Role of Preoperative Chemoradiotherapy in Clinical Stage Ⅱ/Ⅲ Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis[J/OL]. Front Oncol, 2020, 10 [2022-02-20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848147/pdf/fonc-10-609313.pdf. DOI: 10.3389/fonc.2020.609313.
[7]
Ryan JE, Warrier SK, Lynch AC, et al. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review[J]. Colorectal Dis, 2016, 18(3): 234-246. DOI: 10.1111/codi.13207.
[8]
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. DOI: 10.1016/S0140-6736(13)62422-8.
[9]
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010, 11(9): 835-844. DOI: 10.1016/S1470-2045(10)70172-8.
[10]
Smith JJ, Strombom P, Chow OS, et al. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy[J/OL]. JAMA Oncol, 2019, 5(4) [2022-02-20]. https://jamanetwork.com/journals/jamaoncology/fullarticle/2720474. DOI: 10.1001/jamaoncol.2018.5896.
[11]
Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis[J]. Lancet Oncol, 2016, 17(2): 174-183. DOI: 10.1016/S1470-2045(15)00467-2.
[12]
Smith FM, Cresswell K, Myint AS, et al. Is "watch-and-wait" after chemoradiotherapy safe in patients with rectal cancer?[J/OL]. BMJ, 2018, 363 [2022-02-20]. https://www.bmj.com/content/363/bmj.k4472.long. DOI: 10.1136/bmj.k4472.
[13]
Wang QX, Zhang R, Xiao WW, et al. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy[J/OL]. Radiat Oncol, 2021, 16(1) [2022-02-20]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-021-01746-0. DOI: 10.1186/s13014-021-01746-0.
[14]
Dossa F, Chesney TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2017, 2(7): 501-513. DOI: 10.1016/S2468-1253(17)30074-2.
[15]
Dattani M, Heald RJ, Goussous G, et al. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis[J]. Ann Surg, 2018, 268(6): 955-967. DOI: 10.1097/SLA.0000000000002761.
[16]
van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study[J]. Lancet, 2018, 391(10139): 2537-2545. DOI: 10.1016/S0140-6736(18)31078-X.
[17]
Granata V, Grassi R, Fusco R, et al. Current status on response to treatment in locally advanced rectal cancer: what the radiologist should know[J]. Eur Rev Med Pharmacol Sci, 2020, 24(23): 12050-12062. DOI: 10.26355/eurrev_202012_23994.
[18]
Jhaveri KS, Hosseini-Nik H. MRI of Rectal Cancer: An Overview and Update on Recent Advances[J]. AJR Am J Roentgenol, 2015, 205(1): W42-W55. DOI: 10.2214/AJR.14.14201.
[19]
Horvat N, Veeraraghavan H, Khan M, et al. MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy[J]. Radiology, 2018, 287(3): 833-843. DOI: 10.1148/radiol.2018172300.
[20]
Seo N, Kim H, Cho MS, et al. Response Assessment with MRI after Chemoradiotherapy in Rectal Cancer: Current Evidences[J]. Korean J Radiol, 2019, 20(7): 1003-1018. DOI: 10.3348/kjr.2018.0611.
[21]
Sclafani F, Brown G, Cunningham D, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer[J]. Br J Cancer, 2017, 117(10): 1478-1485. DOI: 10.1038/bjc.2017.320.
[22]
De Felice F, Magnante AL, Musio D, et al. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy[J]. Eur J Surg Oncol, 2017, 43(7): 1324-1329. DOI: 10.1016/j.ejso.2017.03.010.
[23]
Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting[J]. Eur Radiol, 2018, 28(4): 1465-1475. DOI: 10.1007/s00330-017-5026-2.
[24]
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8): 529-536. DOI: 10.7326/0003-4819-155-8-201110180-00009.
[25]
Bassaneze T, Gonçalves JE, Faria JF, et al. Quantitative Aspects of Diffusion-weighted Magnetic Resonance Imaging in Rectal Cancer Response to Neoadjuvant Therapy[J]. Radiol Oncol, 2017, 51(3): 270-276. DOI: 10.1515/raon-2017-0025.
[26]
Blazic IM, Lilic GB, Gajic MM. Quantitative Assessment of Rectal Cancer Response to Neoadjuvant Combined Chemotherapy and Radiation Therapy: Comparison of Three Methods of Positioning Region of Interest for ADC Measurements at Diffusion-weighted MR Imaging[J]. Radiology, 2017, 282(2): 418-428. DOI: 10.1148/radiol.2016151908.
[27]
Cai PQ, Wu YP, An X, et al. Simple measurements on diffusion-weighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Eur Radiol, 2014, 24(11): 2962-2970. DOI: 10.1007/s00330-014-3251-5.
[28]
Chen YG, Chen MQ, Guo YY, et al. Apparent Diffusion Coefficient Predicts Pathology Complete Response of Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy[J/OL]. PLoS One, 2016, 11(4) [2022-02-20]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0153944. DOI: 10.1371/journal.pone.0153944.
[29]
Cho SH, Kim GC, Jang YJ, et al. Locally advanced rectal cancer: post-chemoradiotherapy ADC histogram analysis for predicting a complete response[J]. Acta Radiol, 2015, 56(9): 1042-1050. DOI: 10.1177/0284185114550193.
[30]
Choi MH, Oh SN, Rha SE, et al. Diffusion-weighted imaging: Apparent diffusion coefficient histogram analysis for detecting pathologic complete response to chemoradiotherapy in locally advanced rectal cancer[J]. J Magn Reson Imaging, 2016, 44(1): 212-220. DOI: 10.1002/jmri.25117.
[31]
Curvo-Semedo L, Lambregts DM, Maas M, et al. Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging[J]. Radiology, 2011, 260(3): 734-743. DOI: 10.1148/radiol.11102467.
[32]
Delli Pizzi A, Cianci R, Genovesi D, et al. Performance of diffusion-weighted magnetic resonance imaging at 3.0 T for early assessment of tumor response in locally advanced rectal cancer treated with preoperative chemoradiation therapy[J]. Abdom Radiol (NY), 2018, 43(9): 2221-2230. DOI: 10.1007/s00261-018-1457-8.
[33]
Foti PV, Privitera G, Piana S, et al. Locally advanced rectal cancer: Qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapy[J]. Eur J Radiol Open, 2016, 3: 145-152. DOI: 10.1016/j.ejro.2016.06.003.
[34]
Genovesi D, Filippone A, Ausili Cèfaro G, et al. Diffusion-weighted magnetic resonance for prediction of response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results of a monoinstitutional prospective study[J]. Eur J Surg Oncol, 2013, 39(10): 1071-1078. DOI: 10.1016/j.ejso.2013.07.090.
[35]
Gurdal N, Fayda M, Alishev N, et al. Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers[J]. Tumori, 2018, 104(4): 266-272. DOI: 10.5301/tj.5000702.
[36]
Ha HI, Kim AY, Yu CS, et al. Locally advanced rectal cancer: diffusion-weighted MR tumour volumetry and the apparent diffusion coefficient for evaluating complete remission after preoperative chemoradiation therapy[J]. Eur Radiol, 2013, 23(12): 3345-3353. DOI: 10.1007/s00330-013-2936-5.
[37]
Hu F, Tang W, Sun Y, et al. The value of diffusion kurtosis imaging in assessing pathological complete response to neoadjuvant chemoradiation therapy in rectal cancer: a comparison with conventional diffusion-weighted imaging[J]. Oncotarget, 2017, 8(43): 75597-75606. DOI: 10.18632/oncotarget.17491.
[38]
Intven M, Monninkhof EM, Reerink O, et al. Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after neo-adjuvant chemoradiation in locally advanced rectal cancer[J]. Acta Oncol, 2015, 54(10): 1729-1736. DOI: 10.3109/0284186x.2015.1037010.
[39]
Intven M, Reerink O, Philippens ME. Diffusion-weighted MRI in locally advanced rectal cancer : pathological response prediction after neo-adjuvant radiochemotherapy[J]. Strahlenther Onkol, 2013, 189(2): 117-122. DOI: 10.1007/s00066-012-0270-5.
[40]
Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy[J]. Radiology, 2009, 253(1): 116-125. DOI: 10.1148/radiol.2532090027.
[41]
Kim SH, Lee JY, Lee JM, et al. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer[J]. Eur Radiol, 2011, 21(5): 987-995. DOI: 10.1007/s00330-010-1989-y.
[42]
Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer[J]. Acta Oncol, 2010, 49(7): 956-963. DOI: 10.3109/0284186x.2010.498439.
[43]
Lambrecht M, Vandecaveye V, De Keyzer F, et al. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 863-870. DOI: 10.1016/j.ijrobp.2010.12.063.
[44]
Liang CY, Chen MD, Zhao XX, et al. Multiple mathematical models of diffusion-weighted magnetic resonance imaging combined with prognostic factors for assessing the response to neoadjuvant chemotherapy and radiation therapy in locally advanced rectal cancer[J]. Eur J Radiol, 2019, 110: 249-255. DOI: 10.1016/j.ejrad.2018.12.005.
[45]
Napoletano M, Mazzucca D, Prosperi E, et al. Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy[J]. Abdom Radiol (NY), 2019, 44(11): 3664-3673. DOI: 10.1007/s00261-019-02012-4.
[46]
Palmisano A, Di Chiara A, Esposito A, et al. MRI prediction of pathological response in locally advanced rectal cancer: when apparent diffusion coefficient radiomics meets conventional volumetry[J/OL]. Clin Radiol, 2020, 75(10) [2022-02-20]. https://www.sciencedirect.com/science/article/pii/S0009926020302567?via%3Dihub. DOI: 10.1016/j.crad.2020.06.023.
[47]
Petrillo A, Fusco R, Granata V, et al. Assessing response to neo-adjuvant therapy in locally advanced rectal cancer using Intra-voxel Incoherent Motion modelling by DWI data and Standardized Index of Shape from DCE-MRI[J/OL]. Ther Adv Med Oncol, 2018, 10 [2022-2-20]. https://journals.sagepub.com/doi/pdf/10.1177/1758835918809875. DOI: 10.1177/1758835918809875.
[48]
Tarallo N, Angeretti MG, Bracchi E, et al. Magnetic resonance imaging in locally advanced rectal cancer: quantitative evaluation of the complete response to neoadjuvant therapy[J/OL]. Pol J Radiol, 2018, 83 [2022-02-20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384410/pdf/PJR-83-81156.pdf. DOI: 10.5114/pjr.2018.81156.
[49]
Yang L, Xia C, Liu D, et al. The role of readout-segmented echo-planar imaging-based diffusion-weighted imaging in evaluating tumor response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy[J]. Acta Radiol, 2020, 61(9): 1155-1164. DOI: 10.1177/0284185119897354.
[50]
Yang L, Xia C, Zhao J, et al. The value of intravoxel incoherent motion and diffusion kurtosis imaging in the assessment of tumor regression grade and T stages after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer[J/OL]. Eur J Radiol, 2021, 136 [2022-02-20]. https://www.sciencedirect.com/science/article/pii/S0720048X2030694X?via%3Dihub. DOI: 10.1016/j.ejrad.2020.109504.
[51]
Yang L, Qiu M, Xia C, et al. Value of high-resolution DWI in combination with texture analysis for the evaluation of tumor response after preoperative chemoradiotherapy for locally advanced rectal cancer[J]. AJR Am J Roentgenol, 2019, 212(6): 1279-1286. DOI: 10.2214/AJR.18.20689.
[52]
Zhu HB, Zhang XY, Zhou XH, et al. Assessment of pathological complete response to preoperative chemoradiotherapy by means of multiple mathematical models of diffusion-weighted MRI in locally advanced rectal cancer: A prospective single-center study[J]. J Magn Reson Imaging, 2017, 46(1): 175-183. DOI: 10.1002/jmri.25567.
[53]
Hu FX, Tong T, Peng WJ. Diffusion kurtosis imaging: assessment of pathological complete response to neoadjuvant chemoradiation therapy in rectal cancer[J]. Oncoradiology, 2017, 26(1): 49-57. DOI: 10.3969/j.issn.1008-617X.2017.01.009.
[54]
Su JN, Mai SS, Chen Y, et al. Diffusion-weighted imaging for assessing complete response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Journal of Guangdong Medical University, 2020, 38(4): 474-478. DOI: 10.3969/j.issn.1005-4057.2020.04.025.
[55]
Xiao L, Zhu LN, Zhao ZW, et al. Multiple parameters of magnetic resonance imaging for assessing the response to neoadjuvant chemotherapy and radiation therapy in locally advanced rectal cancer[J]. Journal of Clinical Radiology, 2021, 40(4): 751-756. DOI: 10.13437/j.cnki.jcr.2021.04.028.
[56]
Xiao Q, Ye F, Jin J, et al. Predictive value of apparent diffusion coefficient for effi cacy of preoperative chemoradiotherapy for locally advanced rectal cancer[J]. Chin J Radiat Oncol, 2014, 23(3): 194-198. DOI: 10.3760/cma.j.issn.1004-4221.2014.03.005.
[57]
Yang LQ, Xia CC, Wu B. Study on the correlation between ADC value of high-resolution diffusion-weighted imaging and tumor regression grade after neoadjuvant therapy for rectal cancer[J]. J Sichuan Univ (Med Sci Edi), 2018, 49(6): 970-973. DOI: 10.13464/j.scuxbyxb.2018.06.030.
[58]
Barral M, Eveno C, Hoeffel C, et al. Diffusion-weighted magnetic resonance imaging in colorectal cancer[J]. J Visc Surg, 2016, 153(5): 361-369. DOI: 10.1016/j.jviscsurg.2016.08.004.
[59]
Chandramohan A, Siddiqi UM, Mittal R, et al. Diffusion weighted imaging improves diagnostic ability of MRI for determining complete response to neoadjuvant therapy in locally advanced rectal cancer[J/OL]. Eur J Radiol Open, 2020, 7 [2022-2-20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044654/pdf/main.pdf. DOI: 10.1016/j.ejro.2020.100223.
[60]
Lambregts DMJ, Delli Pizzi A, Lahaye MJ, et al. A Pattern-Based Approach Combining Tumor Morphology on MRI With Distinct Signal Patterns on Diffusion-Weighted Imaging to Assess Response of Rectal Tumors After Chemoradiotherapy[J]. Dis Colon Rectum, 2018, 61(3): 328-337. DOI: 10.1097/dcr.0000000000000915.
[61]
Pham TT, Liney GP, Wong K, et al. Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer[J/OL]. Br J Radiol, 2017, 90(1072) [2022-02-20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605058/pdf/bjr.20151078.pdf. DOI: 10.1259/bjr.20151078.
[62]
Lambregts DM, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study[J]. Ann Surg Oncol, 2011, 18(8): 2224-2231. DOI: 10.1245/s10434-011-1607-5.
[63]
Amodeo S, Rosman AS, Desiato V, et al. MRI-Based Apparent Diffusion Coefficient for Predicting Pathologic Response of Rectal Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis[J]. AJR Am J Roentgenol, 2018, 211(5): W205-W216. DOI: 10.2214/ajr.17.19135.
[64]
Chen K, She HL, Wu T, et al. Comparison of percentage changes in quantitative diffusion parameters for assessing pathological complete response to neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis[J]. Abdom Radiol (NY), 2021, 46(3): 894-908. DOI: 10.1007/s00261-020-02770-6.
[65]
Probst CP, Becerra AZ, Aquina CT, et al. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation[J]. J Am Coll Surg, 2015, 221(2): 430-440. DOI: 10.1016/j.jamcollsurg.2015.04.010.
[66]
Lefevre JH, Mineur L, Cachanado M, et al. Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial[J]. Ann Surg, 2019, 270(5): 747-754. DOI: 10.1097/SLA.0000000000003530.
[67]
Lefevre JH, Mineur L, Kotti S, et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)[J]. J Clin Oncol, 2016, 34(31): 3773-3780. DOI: 10.1200/JCO.2016.67.6049.
[68]
Huntington CR, Boselli D, Symanowski J, et al. Optimal Timing of Surgical Resection After Radiation in Locally Advanced Rectal Adenocarcinoma: An Analysis of the National Cancer Database[J]. Ann Surg Oncol, 2016, 23(3): 877-887. DOI: 10.1245/s10434-015-4927-z.
[69]
Sun Z, Adam MA, Kim J, et al. Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer[J]. J Am Coll Surg, 2016, 222(4): 367-374. DOI: 10.1016/j.jamcollsurg.2015.12.017.
[70]
Chinese protocol of diagnosis and treatment of colorectal cancer(2020 edition)[J]. Chin J Surg, 2020, 58(8): 561-585. DOI: 10.3760/cma.j.cn112139-20200518-00390.

PREV Prediction of lymph node metastasis of pancreatic ductal adenocarcinoma based on radiomics model of T1WI arterial phase
NEXT Prediction and risk assessment of benign and malignant prostate lesions based on Bp-MRI radiomics
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn